Literature DB >> 33258165

Viral nucleoprotein antibodies activate TRIM21 and induce T cell immunity.

Sarah L Caddy1,2, Marina Vaysburd1, Guido Papa1, Mark Wing1, Kevin O'Connell1, Diana Stoycheva3, Stian Foss4,5, Jan Terje Andersen4,5, Annette Oxenius3, Leo C James1.   

Abstract

Nucleoprotein (N) is an immunodominant antigen in many enveloped virus infections. While the diagnostic value of anti-N antibodies is clear, their role in immunity is not. This is because while they are non-neutralising, they somehow clear infection by coronavirus, influenza and LCMV in vivo. Here, we show that anti-N immune protection is mediated by the cytosolic Fc receptor and E3 ubiquitin ligase TRIM21. Exploiting LCMV as a model system, we demonstrate that TRIM21 uses anti-N antibodies to target N for cytosolic degradation and generate cytotoxic T cells (CTLs) against N peptide. These CTLs rapidly eliminate N-peptide-displaying cells and drive efficient viral clearance. These results reveal a new mechanism of immune synergy between antibodies and T cells and highlights N as an important vaccine target.
© 2020 The Authors. Published under the terms of the CC BY 4.0 license.

Entities:  

Keywords:  TRIM21; antibody; non-neutralising; nucleoprotein; virus

Mesh:

Substances:

Year:  2020        PMID: 33258165      PMCID: PMC7917548          DOI: 10.15252/embj.2020106228

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   14.012


  42 in total

1.  Distinct proteolytic processes generate the C and N termini of MHC class I-binding peptides.

Authors:  X Y Mo; P Cascio; K Lemerise; A L Goldberg; K Rock
Journal:  J Immunol       Date:  1999-12-01       Impact factor: 5.422

2.  Regulation of virus neutralization and the persistent fraction by TRIM21.

Authors:  W A McEwan; F Hauler; C R Williams; S R Bidgood; D L Mallery; R A Crowther; L C James
Journal:  J Virol       Date:  2012-05-30       Impact factor: 5.103

3.  The dominant role of CD8+ dendritic cells in cross-presentation is not dictated by antigen capture.

Authors:  Petra Schnorrer; Georg M N Behrens; Nicholas S Wilson; Joanne L Pooley; Christopher M Smith; Dima El-Sukkari; Gayle Davey; Fiona Kupresanin; Ming Li; Eugene Maraskovsky; Gabrielle T Belz; Francis R Carbone; Ken Shortman; William R Heath; Jose A Villadangos
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-28       Impact factor: 11.205

4.  Non-neutralizing antibodies protect from chronic LCMV infection independently of activating FcγR or complement.

Authors:  Kirsten Richter; Annette Oxenius
Journal:  Eur J Immunol       Date:  2013-07-15       Impact factor: 5.532

5.  Induction of endoplasmic reticulum-endosome fusion for antigen cross-presentation induced by poly (γ-glutamic acid) nanoparticles.

Authors:  Yohei Mukai; Tomoyo Yoshinaga; Mai Yoshikawa; Kazuhiko Matsuo; Tomoaki Yoshikawa; Keisuke Matsuo; Kazuyuki Niki; Yasuo Yoshioka; Naoki Okada; Shinsaku Nakagawa
Journal:  J Immunol       Date:  2011-11-16       Impact factor: 5.422

6.  TRIM21 Immune Signaling Is More Sensitive to Antibody Affinity Than Its Neutralization Activity.

Authors:  Stian Foss; Ruth E Watkinson; Algirdas Grevys; Martin B McAdam; Malin Bern; Lene Stokken Høydahl; Bjørn Dalhus; Terje E Michaelsen; Inger Sandlie; Leo C James; Jan Terje Andersen
Journal:  J Immunol       Date:  2016-03-09       Impact factor: 5.422

7.  Major histocompatibility complex class I presentation of peptides derived from soluble exogenous antigen by a subset of cells engaged in phagocytosis.

Authors:  C Reis e Sousa; R N Germain
Journal:  J Exp Med       Date:  1995-09-01       Impact factor: 14.307

8.  Similar antigen cross-presentation capacity and phagocytic functions in all freshly isolated human lymphoid organ-resident dendritic cells.

Authors:  Elodie Segura; Mélanie Durand; Sebastian Amigorena
Journal:  J Exp Med       Date:  2013-04-08       Impact factor: 14.307

9.  Evaluation of Nucleocapsid and Spike Protein-Based Enzyme-Linked Immunosorbent Assays for Detecting Antibodies against SARS-CoV-2.

Authors:  Wanbing Liu; Lei Liu; Guomei Kou; Yaqiong Zheng; Yinjuan Ding; Wenxu Ni; Qiongshu Wang; Li Tan; Wanlei Wu; Shi Tang; Zhou Xiong; Shangen Zheng
Journal:  J Clin Microbiol       Date:  2020-05-26       Impact factor: 5.948

10.  A Method for the Acute and Rapid Degradation of Endogenous Proteins.

Authors:  Dean Clift; William A McEwan; Larisa I Labzin; Vera Konieczny; Binyam Mogessie; Leo C James; Melina Schuh
Journal:  Cell       Date:  2017-11-16       Impact factor: 41.582

View more
  19 in total

Review 1.  Vaccinal antibodies: Fc antibody engineering to improve the antiviral antibody response and induce vaccine-like effects.

Authors:  Dhuha H Nawab
Journal:  Hum Vaccin Immunother       Date:  2021-11-29       Impact factor: 3.452

2.  Functional skewing of TRIM21-SIRT5 interplay dictates IL-1β production in DSS-induced colitis.

Authors:  Pengbo Yao; Taiqi Chen; Peng Jiang; Li Li; Wenjing Du
Journal:  EMBO Rep       Date:  2022-06-30       Impact factor: 9.071

3.  Development and preclinical evaluation of virus-like particle vaccine against COVID-19 infection.

Authors:  Ismail Cem Yilmaz; Emre Mert Ipekoglu; Artun Bulbul; Nilsu Turay; Muzaffer Yildirim; Irem Evcili; Naz Surucu Yilmaz; Nese Guvencli; Yagmur Aydin; Bilgi Gungor; Berfu Saraydar; Asli Gulce Bartan; Bilgehan Ibibik; Tugce Bildik; İlayda Baydemir; Hatice Asena Sanli; Basak Kayaoglu; Yasemin Ceylan; Tugce Yildirim; Irem Abras; Ihsan Cihan Ayanoglu; Sefa Burak Cam; Eda Ciftci Dede; Merve Gizer; Osman Erganis; Fahriye Sarac; Serdar Uzar; Hakan Enul; Cumhur Adiay; Gamze Aykut; Hivda Polat; Ismail Selim Yildirim; Saban Tekin; Gulay Korukluoglu; Hasan Ersin Zeytin; Petek Korkusuz; Ihsan Gursel; Mayda Gursel
Journal:  Allergy       Date:  2021-09-21       Impact factor: 14.710

4.  Target-induced clustering activates Trim-Away of pathogens and proteins.

Authors:  Jingwei Zeng; Ana Filipa Santos; Aamir S Mukadam; Mariana Osswald; David A Jacques; Claire F Dickson; Stephen H McLaughlin; Christopher M Johnson; Leo Kiss; Jakub Luptak; Nadine Renner; Marina Vaysburd; William A McEwan; Eurico Morais-de-Sá; Dean Clift; Leo C James
Journal:  Nat Struct Mol Biol       Date:  2021-02-25       Impact factor: 15.369

5.  Intensified antibody response elicited by boost suggests immune memory in individuals administered two doses of SARS-CoV-2 inactivated vaccine.

Authors:  Yun Liao; Ying Zhang; Heng Zhao; Jing Pu; Zhimei Zhao; Dandan Li; Shengtao Fan; Li Yu; Xingli Xu; Lichun Wang; Guorun Jiang; Longding Liu; Qihan Li
Journal:  Emerg Microbes Infect       Date:  2021-12       Impact factor: 7.163

Review 6.  TRIM21/Ro52 - Roles in Innate Immunity and Autoimmune Disease.

Authors:  Esther L Jones; Stephen M Laidlaw; Lynn B Dustin
Journal:  Front Immunol       Date:  2021-09-06       Impact factor: 7.561

7.  Multicomponent vaccines to fight SARS-CoV-2 variants of concern.

Authors:  Antonio Cassone; Roberto Cauda
Journal:  Vaccine       Date:  2021-11-01       Impact factor: 3.641

8.  Analysis of Serological Biomarkers of SARS-CoV-2 Infection in Convalescent Samples From Severe, Moderate and Mild COVID-19 Cases.

Authors:  Javier Castillo-Olivares; David A Wells; Matteo Ferrari; Andrew C Y Chan; Peter Smith; Angalee Nadesalingam; Minna Paloniemi; George W Carnell; Luis Ohlendorf; Diego Cantoni; Martin Mayora-Neto; Phil Palmer; Paul Tonks; Nigel J Temperton; David Peterhoff; Patrick Neckermann; Ralf Wagner; Rainer Doffinger; Sarah Kempster; Ashley D Otter; Amanda Semper; Tim Brooks; Anna Albecka; Leo C James; Mark Page; Wilhelm Schwaeble; Helen Baxendale; Jonathan L Heeney
Journal:  Front Immunol       Date:  2021-11-19       Impact factor: 7.561

9.  A longitudinal follow-up of COVID-19 patients in the convalescent phase showed recovery in radiological results, the dynamics of lymphocytes, and a decrease in the level of IgG antibody: a single-centre, observational study.

Authors:  Ziqi Wang; Li Yang; Yi Chen; Zhiwei Xu; Hui Wang; Xiaoju Zhang
Journal:  J Thorac Dis       Date:  2021-05       Impact factor: 2.895

10.  Viral nucleoprotein antibodies activate TRIM21 and induce T cell immunity.

Authors:  Sarah L Caddy; Marina Vaysburd; Guido Papa; Mark Wing; Kevin O'Connell; Diana Stoycheva; Stian Foss; Jan Terje Andersen; Annette Oxenius; Leo C James
Journal:  EMBO J       Date:  2020-12-01       Impact factor: 14.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.